Treating severe sepsis with drotrecogin alfa (activated).

Suppr

超能文献

作者信息

Wyncoll Duncan

机构信息

St Thomas' Hospital, London SE1 7EH.

出版信息

Hosp Med. 2003 Mar;64(3):168-72. doi: 10.12968/hosp.2003.64.3.1800.

DOI:10.12968/hosp.2003.64.3.1800

PMID:12669484

Abstract

Severe sepsis is a complex condition with mortality rates ranging from 30 to 50% in spite of advances in critical care. Xigris (drotrecogin alfa (activated)) is associated with an absolute reduction in the risk of death of 6.1% and was granted European Union marketing authorization in August 2002.

摘要